Literature DB >> 16847055

Epidermal growth factor protects prostate cancer cells from apoptosis by inducing BAD phosphorylation via redundant signaling pathways.

Konduru S R Sastry1, Yelena Karpova, George Kulik.   

Abstract

Protection from apoptosis by receptor tyrosine kinases, resistant to the inhibition of phosphatidylinositol 3 '-kinase/Akt and Ras/MEK pathways, has been reported in several cell types, including fibroblasts and epithelial prostate cancer cells; however, mechanisms of this effect were not clear. Here we report that in prostate cancer cells, epidermal growth factor activates two antiapoptotic signaling pathways that impinge on the proapoptotic protein BAD. One signaling cascade operates via the Ras/MEK module and induces BAD phosphorylation on Ser112. Another pathway predominantly relies on Rac/PAK1 signaling that leads to BAD phosphorylation on Ser136. Each of these two pathways is sufficient to protect cells from apoptosis, and therefore both have to be inhibited simultaneously to block epidermal growth factor-dependent survival. Redundancy of antiapoptotic signaling pathways should be considered when therapies targeting antiapoptotic mechanisms are designed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16847055     DOI: 10.1074/jbc.M511485200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  23 in total

1.  Dual inhibition of ERK1/2 and AKT pathways is required to suppress the growth and survival of endometriotic cells and lesions.

Authors:  Joe A Arosh; Sakhila K Banu
Journal:  Mol Cell Endocrinol       Date:  2018-12-20       Impact factor: 4.102

2.  Paxillin regulates androgen- and epidermal growth factor-induced MAPK signaling and cell proliferation in prostate cancer cells.

Authors:  Aritro Sen; Katherine O'Malley; Zhou Wang; Ganesh V Raj; Donald B Defranco; Stephen R Hammes
Journal:  J Biol Chem       Date:  2010-07-13       Impact factor: 5.157

Review 3.  Colon cancer and the epidermal growth factor receptor: Current treatment paradigms, the importance of diet, and the role of chemoprevention.

Authors:  Baldeep Pabla; Marc Bissonnette; Vani J Konda
Journal:  World J Clin Oncol       Date:  2015-10-10

4.  Activating stress-activated protein kinase-mediated cell death and inhibiting epidermal growth factor receptor signaling: a promising therapeutic strategy for prostate cancer.

Authors:  Raj Kumar; Sowmyalakshmi Srinivasan; Pallab Pahari; Jürgen Rohr; Chendil Damodaran
Journal:  Mol Cancer Ther       Date:  2010-08-24       Impact factor: 6.261

5.  Regulation of prostate cancer cell survival by protein kinase Cepsilon involves bad phosphorylation and modulation of the TNFalpha/JNK pathway.

Authors:  John Meshki; M Cecilia Caino; Vivian A von Burstin; Erin Griner; Marcelo G Kazanietz
Journal:  J Biol Chem       Date:  2010-06-21       Impact factor: 5.157

6.  Epidermal growth factor abrogates hypoxia-induced apoptosis in cultured human trophoblasts through phosphorylation of BAD Serine 112.

Authors:  Rachel G Humphrey; Christina Sonnenberg-Hirche; Steven D Smith; Chaobin Hu; Aaron Barton; Yoel Sadovsky; D Michael Nelson
Journal:  Endocrinology       Date:  2008-02-14       Impact factor: 4.736

7.  β2-adrenoreceptor Signaling Increases Therapy Resistance in Prostate Cancer by Upregulating MCL1.

Authors:  Sazzad Hassan; Ashok Pullikuth; Kyle C Nelson; Anabel Flores; Yelena Karpova; Daniele Baiz; Sinan Zhu; Guangchao Sui; Yue Huang; Young A Choi; Ralph D'Agostino; Ashok Hemal; Urs von Holzen; Waldemar Debinski; George Kulik
Journal:  Mol Cancer Res       Date:  2020-09-14       Impact factor: 5.852

8.  Synthesis and characterization of a novel prostate cancer-targeted phosphatidylinositol-3-kinase inhibitor prodrug.

Authors:  Daniele Baiz; Tanya A Pinder; Sazzad Hassan; Yelena Karpova; Freddie Salsbury; Mark E Welker; George Kulik
Journal:  J Med Chem       Date:  2012-09-10       Impact factor: 7.446

9.  Targeting proapoptotic protein BAD inhibits survival and self-renewal of cancer stem cells.

Authors:  K S R Sastry; M A Al-Muftah; Pu Li; M K Al-Kowari; E Wang; A Ismail Chouchane; D Kizhakayil; G Kulik; F M Marincola; A Haoudi; L Chouchane
Journal:  Cell Death Differ       Date:  2014-09-12       Impact factor: 15.828

10.  Pancreatic cancer cells resistance to gemcitabine: the role of MUC4 mucin.

Authors:  S Bafna; S Kaur; N Momi; S K Batra
Journal:  Br J Cancer       Date:  2009-09-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.